Beta-Amyloid (3-40) – 0.1 mg

Overview

Experience a more profound understanding of neurodegenerative conditions with our Beta-Amyloid (3-40) peptide. This product offers a high-purity, N-terminally truncated version of beta-Amyloid (1-40), specifically designed for researchers exploring the complex nature of Alzheimer’s disease. The non-pyroglutamate form, integral to your studies, enables better observation of the aggregation properties and toxicity associated with beta-Amyloid formations.

Key Features

• N-terminally truncated beta-Amyloid (3-40) peptide
• Non-pyroglutamate variant for accurate research
• Highly pure and stable for reliable results
• Essential for studying senile plaques in Alzheimer’s research
• Increased aggregation propensity compared to non-modified forms

Specifications

FAQ

What is the significance of the N-terminal truncation?

N-terminally truncated forms of beta-Amyloid, such as Aß(3-40), are known to be major components of senile plaques, making them critical for studying Alzheimer’s disease pathology.

How does the non-pyroglutamate form differ from other beta-Amyloid peptides?

This non-pyroglutamate beta-Amyloid (3-40) is less prone to degradation and provides a better model for examining the toxicity and aggregation behavior essential to research.

What applications can I use this peptide for?

This peptide is ideal for laboratory studies focused on neurodegenerative diseases, particularly those investigating the biochemical role of beta-Amyloid in Alzheimer’s pathology.

Explore related products such as PKG Substrate or Autocamtide-2 to complement your research. For more options on peptides, visit our peptides category for a comprehensive selection that meets your research needs.

Related Products

• CREBtide [KRREILSRRPSYR], 5-FAM labeled